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Tissue-Specific Remodeling of the Mitochondrial
Proteome in Type 1 Diabetic Akita Mice
Heiko Bugger,1 Dong Chen,2,3 Christian Riehle,1 Jamie Soto,1 Heather A. Theobald,1 Xiao X. Hu,1
Balasubramanian Ganesan,2,3 Bart C. Weimer,2,3 and E. Dale Abel1
OBJECTIVE—To elucidate the molecular basis for mitochon-
drial dysfunction, which has been implicated in the pathogenesis
of diabetes complications.
RESEARCH DESIGN AND METHODS—Mitochondrial matrix
and membrane fractions were generated from liver, brain, heart,
and kidney of wild-type and type 1 diabetic Akita mice. Compar-
ative proteomics was performed using label-free proteome ex-
pression analysis. Mitochondrial state 3 respirations and ATP
synthesis were measured, and mitochondrial morphology was
evaluated by electron microscopy. Expression of genes that
regulate mitochondrial biogenesis, substrate utilization, and ox-
idative phosphorylation (OXPHOS) were determined.
RESULTS—In diabetic mice, fatty acid oxidation (FAO) pro-
teins were less abundant in liver mitochondria, whereas FAO
protein content was induced in mitochondria from all other
tissues. Kidney mitochondria showed coordinate induction of
tricarboxylic acid (TCA) cycle enzymes, whereas TCA cycle
proteins were repressed in cardiac mitochondria. Levels of
OXPHOS subunits were coordinately increased in liver mitochon-
dria, whereas mitochondria of other tissues were unaffected. Mito-
chondrial respiration, ATP synthesis, and morphology were
unaffected in liver and kidney mitochondria. In contrast, state
3 respirations, ATP synthesis, and mitochondrial cristae den-
sity were decreased in cardiac mitochondria and were accom-
panied by coordinate repression of OXPHOS and peroxisome
proliferator–activated receptor (PPAR)- coactivator (PGC)-1
transcripts.
CONCLUSIONS—Type 1 diabetes causes tissue-specific remod-
eling of the mitochondrial proteome. Preservation of mitochon-
drial function in kidney, brain, and liver, versus mitochondrial
dysfunction in the heart, supports a central role for mitochon-
drial dysfunction in diabetic cardiomyopathy. Diabetes 58:
1986–1997, 2009
Type 1 diabetes reduces lifespan in affected hu-mans, mainly because of complications such ascardiovascular disease and diabetic nephropathy(1,2). Substrate utilization is altered in several
diabetic tissues. For example, myocardial fatty acid oxi-
dation (FAO) and hepatic gluconeogenesis are increased
(3,4). Changes in metabolite or hormone concentrations,
such as reduced insulin and increased glucagon levels,
may alter energy metabolism in diabetes. Moreover, acti-
vation of signaling cascades, such as the peroxisome
proliferator–activated receptor (PPAR)- coactivator
(PGC)-1 signaling pathway, may in turn modulate gene
expression of oxidative phosphorylation (OXPHOS) pro-
teins and enzymes of energy substrate metabolism (4–7).
Several groups have investigated mitochondrial function
in type 1 diabetic tissues, reporting mitochondrial oxida-
tive stress and impairment of mitochondrial respiration
and OXPHOS complex activities in various tissues (3,5,8–
11). However, the molecular basis for the impairment in
diabetes remains incompletely understood.
Gene expression profiling studies in liver and kidney
tissue of type 1 diabetic rodents reveal significant associ-
ations between diabetes and changes in gene expression
(12,13). Microarray analyses of cardiac tissue from strep-
tozotocin-induced diabetic rats found 13% of 1,614 regu-
lated genes encoding for mitochondrial proteins. Of note,
expression of genes encoding FAO proteins were in-
creased (14). Shen et al. (11) identified 20 significantly
regulated myocardial proteins in type 1 diabetic OVE26
mice using two-dimensional gel electrophoresis, 12 of
which were identified as mitochondrial proteins. Turko et
al. (15) identified 30 regulated mitochondrial proteins
when assessing cardiac mitochondrial proteins alone.
They also observed increased mitochondrial FAO proteins
and reduced content of a few OXPHOS protein subunits in
myocardium of streptozotocin-induced diabetic rats. How-
ever, many mitochondrial proteins remained undetected in
these studies due to the methodological limitations of
gel-based comparative proteomics. Recently, Johnson et
al. (16) used a semiquantitative liquid chromatography/
mass spectrometry (LC/MS) approach to investigate
whole-cell protein expression changes in liver and heart
tissue of type 1 diabetic BB-DP rats. They reported 365
significantly regulated hepatic proteins in diabetic ani-
mals, a subset of which were mitochondrial proteins.
While the dataset was used to generate hypotheses about
diabetes-induced changes in liver metabolism, metabolic
flux rates were not determined and patterns of protein
expression were not compared between tissues (16). To
our knowledge, no studies have systematically investi-
gated differences in the mitochondrial proteome across
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tissues in type 1 diabetes and related these to changes in
mitochondrial function.
The hypothesis for this study is that mitochondrial
dysfunction contributes to diabetes complications and
that diabetes induces tissue-independent proteomic
changes in mitochondria, thereby compromising mito-
chondrial function. Thus, we examined tissues in wild-type
and type 1 diabetic Akita mice (Akita), which are known
targets of diabetes complications, namely cardiac, renal,
and brain tissue. Liver mitochondria were also examined
to determine whether changes in mitochondrial function
and proteins were uniform across multiple tissues. Akita
mice are a genetic model of type 1 diabetes that circum-
vent potential extrapancreatic toxic effects of streptozoto-
cin and still develop many typical diabetes complications
(17,18). To increase protein coverage beyond gel-based
approaches, we fractionated mitochondria into matrix and
membrane fractions and analyzed the protein composition
directly using protein expression analysis with LC-tandem
MS (LC-MS/MS). The proteome of each tissue was com-
plemented by measurement of respiratory function in
isolated mitochondria, evaluation of mitochondrial mor-
phology, and gene expression analysis for regulators of
mitochondrial biogenesis, substrate utilization, and oxidative
phosphorylation. We found that type 1 diabetes leads to
remodeling of the proteome that regulates mitochondrial
energy metabolism with distinct changes in each tissue
examined. However, mitochondrial dysfunction was only
evident in the heart, suggesting increased susceptibility of
cardiac mitochondria to diabetes-induced dysfunction.
RESEARCH DESIGN AND METHODS
Male heterozygous Ins2/ Akita mice (C57BL/6) and C57BL/6 controls were
obtained from The Jackson Laboratories (Bar Harbor, ME), were housed at
22°C, were given free access to water and food, had a light cycle of 12 h light
and 12 h dark, and were studied at the age of 12 weeks. Animals were studied
in accordance with protocols approved by the institutional animal care and
use committee of the University of Utah.
Mitochondrial isolation. Livers, hearts, brains, and kidneys were removed
from chloral hydrate–anesthetized animals (1 mg/g body wt) and placed
immediately in ice-cold STE1 buffer (250 mmol/l sucrose, 5 mmol/l Tris/HCl, 2
mmol/l EGTA, pH 7.4). In one set of experiments, heart and kidneys were
excised from the same mouse (within 20 s of anesthesia), and in another set
of experiments, brain and liver were excised from the same mouse (within
30 s of anesthesia). Organs that had to be pooled from different animals were
kept in ice-cold STE1 buffer (5 min) until sufficient numbers of organs were
harvested. Four hearts were pooled, minced, incubated in 2.5 ml STE2 buffer
(STE1 containing [wt/vol] 0.5% BSA, 5 mmol/l MgCl2, 1 mmol/l ATP, and 2.5
units/ml protease type VIII from Bacillus licheniformis) for 4 min, diluted
with 2.5 ml STE1 buffer, and homogenized using a Teflon pistil in a Potter-
Elvejhem glass homogenizer. The homogenate was further diluted with 5 ml
STE1 containing one tablet Complete Mini protease inhibitor cocktail (Roche,
Indianapolis, IN). Similar to hearts, two kidneys (pooled) or one liver were
minced, homogenized in 5 ml STE1 buffer, and further diluted with 5 ml STE1
containing one tablet Complete Mini. Four brains (pooled) were minced,
homogenized in 5 ml isolation medium (250 mmol/l sucrose, 1 mmol/l EDTA,
1 mg/ml BSA, and 0.25 mmol/l dithiothreitol, pH 7.4), and diluted by adding 5
ml isolation medium containing one tablet of Complete Mini. Heart homoge-
nates were centrifuged at 8,000g for 10 min, and the resulting pellet was
resuspended in STE1 buffer and centrifuged at 700g for 10 min. The resulting
supernatant was centrifuged twice at 8,000g for 10 min. Kidney or liver
homogenates were centrifuged at 1,000g for 5 min, and the resulting super-
natant was centrifuged twice at 10,000g for 10 min. Brain homogenates were
centrifuged at 500g for 5 min in four separate tubes. Resulting supernatants
were centrifuged at 15,000g for 5 min; each pellet was resuspended in 150 l
isolation medium, loaded on a Percoll gradient (0.6 ml 23%, 0.6 ml 15%, 0.6 ml
10%, and 0.6 ml 3% Percoll solution), and centrifuged in a swinging-bucket
rotor (Beckman SW55Ti) at 32,500g for 8 min. The nonsynaptic mitochondrial
pellet (bottom layer) was collected, resuspended in 2.5 ml isolation medium,
and centrifuged twice at 10,000g for 10 min. The pellet obtained from each
mitochondrial isolation was resuspended in 1 ml buffer B (250 mmol/l sucrose,
1 mmol/l EDTA, 10 mmol/l Tris/HCl, pH 7.4). All centrifugation steps were
carried out at 4°C.
Mitochondrial purification and fractionation. Mitochondrial isolates were
loaded on a Percoll gradient (2.2 ml 2.5 mol/l sucrose, 6.55 ml Percoll, 12.25 ml
TE [10 mmol/l Tris/HCl, 1 mmol/l EDTA, pH 7.4]) and centrifuged at 60,000g
for 45 min at 4°C as described by Hovius et al. (19). The lower layer was
resuspended in 5 ml of buffer B and centrifuged three times at 10,000g for 10
min at 4°C. The pellet was resuspended in 100 l 10 mmol/l Tris/HCl, pH 8.5,
and freeze-thawed three times (5 min liquid nitrogen/5 min 37°C water bath).
Fractionation was achieved by centrifuging the isolate at 40,000g for 20 min at
4°C. Centrifugation was repeated for the respective supernatant (matrix) and
pellet (membrane) fractions to reduce membrane or matrix protein cross-
contamination. Protein concentrations were determined using the Micro BCA
Protein Assay Kit (Pierce, Rockford, IL).
Protein in-solution tryptic digestion. A total of 5 l of 0.2% RapidGest
(Waters, Manchester, U.K.) was added to 20 g of membrane protein sample
in 15 l H2O. The mixed solution was heated at 80°C for 20 min, and the
protein mixtures were tryptically digested as described by the Waters Protein
Expression System Manual (Waters 2006). After adding NH4HCO3 and treat-
ment with dithiothreitol and iodoacetamide, 4 l of 0.11 g/l trypsin in 25
mmol/l NH4HCO3 was added to the protein sample. Samples were incubated
at 37°C overnight, incubated with 1% formic acid for 30 min at 37°C, and
centrifuged at 10,000g for 10 min. The supernatant was used to determine the
proteome.
Protein expression. Equal amounts of digested protein in a final volume of
3 l were introduced into a Symmetry C18 trapping column (180 mol/l  20
mm) with the NanoACQUITY Sample Manager (Waters) and washed with H2O
for 2 min at 10 ml/min. Using solvent A (99.9% H2O and 0.1% formic acid) and
solvent B (99.9% acetonitrile and 0.1% formic acid), the peptides were eluted
from the trapping column over a 100-m 100-mm BEH 130 C18 column with
a 140-min gradient (1–4% B for 0.1 min, 4–25% B for 89.9 min, 25–35% B for 5
min, 35–85% B for 2 min, 85% B for 13 min, 85–95% B for 8 min, 95–1% B for
2 min, and 1% B for 20 min) at 0.8 l/min flow rate using a NanoACQUITY
UPLC (Waters). The mass spectrometer (MS), Q-TOF Premier (Waters), was
set to a parallel fragmentation mode with scan times of 1.0 s. The low
fragmentation energy was 5 V and the high fragmentation energy was 17–45 V.
Fibrinopeptide B (GLU1) was used as the external calibration standard with
LockSpray. Enolase was used as the internal control. MS spectra were
analyzed by Waters ProteinLynx Global Server 2.3. The following default
setting was used for protein identification: minimum peptide matches per
protein, 1; minimum fragment ion matches per peptide, 3; minimum fragment
ion matches per protein, 7; and the protein false-positive discovery rate, 4%.
The database search algorithm of Waters ProteinLynx Global Server 2.3 was
described by Levin et al. (20). Gene ontology enrichment analysis was
performed using Bioconductor as described before (21). Analyses were
performed on the proteomic dataset of matrix or membrane fractions of liver,
brain, heart, or kidney mitochondria or in matrix or membrane fractions
across all tissues. Gene ontology terms were considered significantly enriched
between wild-type and Akita mice if P 0.05. Canonical pathway analysis was
performed using ingenuity pathways analysis (IPA) (Ingenuity Systems,
Redwood City, CA).
Gene expression analysis. Total RNA was extracted from livers, hearts,
brains, and kidneys with Trizol (Invitrogen, Carlsbad, CA), purified with the
RNEasy Kit (Qiagen, Valencia, CA) and reverse transcribed (3). Equal amounts
of cDNA were subjected to quantitative real-time RT-PCR using SYBR Green as a
probe. Data were normalized by comparison to the invariant transcript 16S RNA.
Primer sequences are presented in online appendix Table S17 (available at
http://diabetes.diabetesjournals.org/cgi/content/full/db09-0259/DC1).
Mitochondrial function. Mitochondria were isolated, as described above,
without addition of protease inhibitors and incubated in respiration medium
(120 mmol/l KCl, 5 mmol/l KH2PO4, 1 mmol/l EGTA, 1 mg/ml BSA, and 3
mmol/l HEPES, pH 7.2, 25°C) containing 5 mmol/l succinate/10 mol/l
rotenone or 5 mmol/l glutamate/2 mmol/l malate or 20 mol/l palmitoyl-
carnitine/2 mmol/l malate. State 2 respiration was measured in the presence of
substrate only, state 3 respiration after addition of adenosine diphosphate
(ADP; 1 mmol/l), and state 4 respiration following complete utilization of the
added ADP. In separate experiments, the uncoupling agent carbonyl cyanide
p-trifluoromethoxyphenylhydrazone (FCCP; 1 mol/l) was added following
addition of ADP in the presence of succinate/rotenone or glutamate/malate as
substrates. ATP synthesis was measured by incubating mitochondria in
respiration medium containing substrates at 25°C. A total of 1 mmol/l ADP
was added, and samples were collected at 10-s intervals following ADP
addition for a total of 60 s. ATP content of the samples was analyzed using a
luminometric assay as previously described (22). Mitochondrial hydrogen
peroxide (H2O2) generation was measured using succinate as a substrate as
previously described (3). To block H2O2 production at complex I, 10 mol/l
H. BUGGER AND ASSOCIATES
DIABETES, VOL. 58, SEPTEMBER 2009 1987
rotenone was added to the reaction. This assay is widely accepted as a
measure of mitochondrial superoxide production.
Tissue ultrastructure. Tissues were freshly excised, immediately washed in
ice-cold saline, and processed for electron microscopy analysis as previously
described (22). Mitochondrial volume density and number were analyzed by
stereology in a blinded fashion using the point-counting method (22,23).
Statistical analysis. Data are presented as means  SE. Statistical analysis
of proteomic data were performed using the Waters ProteinLynx Global
Server version 2.3 software using a clustering algorithm, which chemically
clusters peptide components by mass and retention time for all injected
samples and performs binary comparisons for each experimental condition to
generate an average normalized intensity ratio for all matched AMRT (accu-
rate mass, retention time) components. The Student’s t test was used for each
binary comparison. Respiration, stereology, and gene expression data were
analyzed with Student’s t test using StatView 5.0.1 (SAS Institute, Cary, NC).
Significant differences were accepted at P  0.05.
RESULTS
Mitochondrial protein yields. Akita mice develop se-
vere diabetes at 5–6 weeks of age (18) and were studied at
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the age of 12 weeks. On the day they were killed, Akita
mice were severely hyperglycemic (560  16 vs. 162  10
mg/dl; P  0.05) and were hypertriglyceridemic (114  9
vs. 58  3 mg/dl; P  0.05). Relative changes in protein
abundance between wild-type and Akita mitochondrial
fractions were determined using LC-MS/MS. A total of 218
proteins in liver mitochondria (matrix 83, membrane 135),
295 proteins in brain mitochondria (matrix 154, membrane
141), 123 proteins in cardiac mitochondria (matrix 54,
membrane 69), and 186 proteins in kidney mitochondria
(matrix 87, membrane 99) were identified (supplemen-
tary Table S1). Of all matrix fractions, kidney mitochon-
dria showed the greatest number of proteins with
significant changes in mitochondrial protein content
TABLE 1
Abundance of FAO proteins, TCA cycle enzymes, and OXPHOS subunits in mitochondria of liver, brain, heart, and kidney of Akita,
presented as fold change compared with wild type
Protein Liver Brain Heart Kidney
FAO
Acyl-coenzyme A acyltransferase 2 (mitochondrial 3-oxoacyl-coenzyme A thiolase) 0.75* 1.27† 1.41† 1.69†
Acyl-coenzyme A dehydrogenase, long chain 0.89 1.25† 1.14† 1.18†
Acyl-coenzyme A dehydrogenase, medium chain 0.96 1.12 1.03 0.94
Acyl-coenzyme A dehydrogenase, short chain 0.76* 1.45 1.11 1.03
Carnitine O-octanoyltransferase 0.70 ND ND 0.68*
Dodecenoyl-coenzyme A 	 isomerase (3,2 trans-enoyl-coenyme A isomerase) 0.83* 1.14 1.11 1.32†
Enoyl coenzyme A hydratase, short chain, 1, mitochondrial 1.05 1.00 0.94 1.01
Hydroxyacyl-coenzyme A dehydrogenase/3-ketoacyl-coenzyme A thiolase/enoyl-
coenzyme A hydratase (trifunctional protein), -subunit 1.16 1.33 1.20† 1.52†
TCA cycle
Aconitase 2, mitochondrial 1.07 1.00 0.96 1.32†
Citrate synthase 0.93 0.97 0.86* 1.25†
Fumarate hydratase 1 1.02 1.04 0.90 1.08
Isocitrate dehydrogenase 3 (NAD)  ND 0.87* 0.88* 1.52†
Isocitrate dehydrogenase 3, 
-subunit ND 1.02 1.20 1.15
Malate dehydrogenase 2, NAD (mitochondrial) 0.91 0.97 0.76* 1.30†
Succinate-CoA ligase, GDP forming, -subunit 1.03 0.89 1.19 1.18†
Succinate-coenzyme A ligase, ADP forming, 
-subunit 0.93 0.89 1.00 1.22†
Succinate dehydrogenase Fp subunit 1.15 1.05 0.90 0.98
Succinate dehydrogenase Ip subunit 1.19 0.98 0.96 1.01
Oxidative phosphorylation
ATPase, H /K  transporting, nongastric,  polypeptide ND 0.98 ND ND
ATP synthase, H  transporting, mitochondrial F1 complex, -subunit, isoform 1 1.22† 1.11† 0.99 1.00
ATP synthase, H  transporting mitochondrial F1 complex, 
-subunit 1.23† 1.03 1.09† 1.01
ATP synthase, H  transporting, mitochondrial F1 complex, 	-subunit precursor 0.70* 0.88 ND 0.94
ATP synthase, H  transporting, mitochondrial F1 complex, -subunit 1.02 1.08 1.11 1.00
ATP synthase, H  transporting, mitochondrial F1 complex, O-subunit 1.27† 0.97 0.98 1.05
ATP synthase, H  transporting, mitochondrial F0 complex, subunit b, isoform 1 1.11 0.99 1.00 0.98
ATP synthase, H  transporting, mitochondrial F0 complex, subunit d 1.49† 0.95 1.03 1.04
ATP synthase, H  transporting, mitochondrial F0 complex, subunit F 1.41† 1.28† 1.04 1.03
Cytochrome c oxidase subunit II 1.18 1.00 0.84* 1.11
Cytochrome c oxidase subunit IV isoform 1 1.32† 1.01 1.11 1.09
Cytochrome c oxidase, subunit Va 1.32† 0.82 0.89 1.08
Cytochrome c oxidase, subunit VIb polypeptide 1 1.15 1.11 0.95 1.01
Cytochrome c oxidase, subunit VIIa 1 ND ND 0.95 ND
NADH dehydrogenase (ubiquinone) 1  subcomplex 10 1.33† 1.03 0.76* 1.22†
NADH dehydrogenase (ubiquinone) 1  subcomplex, 4 1.19† 1.06 1.03 1.04
NADH dehydrogenase (ubiquinone) 1  subcomplex, 8 ND 0.99 0.99 0.97
NADH dehydrogenase (ubiquinone) 1  subcomplex, 9 1.56† 0.90 0.93 1.01
NADH dehydrogenase (ubiquinone) 1 
 subcomplex, 10 2.22† 0.88 0.82 1.19
NADH dehydrogenase (ubiquinone) Fe-S protein 1 1.18 1.01 0.84* 1.11
NADH dehydrogenase (ubiquinone) Fe-S protein 2 1.54† 0.93 0.92 1.05
NADH dehydrogenase (ubiquinone) flavoprotein 1 1.37† 0.99 0.87 1.09
Predicted: similar to ATP synthase coupling factor 6, mitochondrial precursor (ATPase
subunit F6) 1.25 1.16 1.04 1.03
Predicted: similar to NADH dehydrogenase (ubiquinone) Fe-S protein 6 ND 1.11 0.95 1.28
Ubiquinol-cytochrome c reductase core protein 1 1.10 0.99 0.88 1.05
Ubiquinol cytochrome c reductase core protein 2 1.12† 0.96 0.92 1.01
Ubiquinol-cytochrome c reductase binding protein 0.84 0.92 1.09 0.98
Ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 1.15 1.01 0.93 1.10
Succinate dehydrogenase Fp subunit 1.15 1.05 0.90 0.98
Succinate dehydrogenase Ip subunit 1.19 0.98 0.96 1.01
*Significantly downregulated proteins. †Significantly upregulated proteins. Symbols indicate a significant difference (P 0.05) compared with
wild type. ND, protein was not detected.
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compared with wild type (52%). Of all membrane frac-
tions, liver mitochondria showed the greatest number of
proteins with significant changes in mitochondrial pro-
tein content compared with wild type (42%). Matrix and
membrane fractions of brain mitochondria exhibited the
lowest number of diabetes-related changes in protein
content (13% in each fraction). Proteins were analyzed
by gene ontology (GO) term enrichment analysis (sup-
plementary Tables S2 and S3 and supplementary Figs.
S4 –S13) and were also sorted by canonical pathway
annotation using the IPA software (supplementary Ta-
bles S14 and S15).
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GO term enrichment analysis. To identify biological
processes that were altered in Akita mitochondria, we
performed a GO term enrichment analysis on the entire
proteomic dataset (pooled from all tissues) in matrix and
membrane fractions, respectively (supplementary Figs. S4
and S5). We generated simplified GO term enrichment
trees for matrix (Fig. 1A) and membrane (Fig. 1B) frac-
tions in the “biological process” category and illustrate the
highly enriched GO terms in Fig. 1. GO terms for energy
metabolic processes were highly enriched in mitochon-
drial matrix fractions of Akita mice, including lipid and
carboxylic acid metabolism, carbohydrate metabolism,
and electron transport (Fig. 1A). In contrast, other GO
terms, such as response to oxidative stress, were less
enriched (supplementary Fig. S4). GO terms of metabolic
processes were also enriched in membrane fractions of
Akita mitochondria, particularly energy generation and
oxidative phosphorylation (Fig. 1B). Thus, we focused
further on mitochondrial energy metabolic pathways, in-
vestigating each organ for common and unique diabetes-
related changes. The proteomic datasets of each tissue
were subjected to canonical pathway analysis using the
IPA software (supplementary Tables S14 and S15), and
selected energy metabolic pathways are presented in
Table 1.
Proteins of FAO. FAO proteins were significantly regu-
lated in Akita mitochondria in all tissues (Table 1). Of the
identified proteins, three of eight FAO proteins were
significantly repressed in liver mitochondria, and all but
two of the remaining FAO proteins were less than wild
TABLE 2
Comparison of gene expression and mitochondrial protein abundance of selected OXPHOS and FAO proteins in liver, brain, heart,
and kidney tissue obtained from wild-type and Akita mice, presented as fold change relative with wild type
Gene Protein
Liver
Oxidative phosphorylation
NADH dehydrogenase (ubiquinone) flavoprotein 1 1.29 1.37†
NADH dehydrogenase (ubiquinone) 1  subcomplex, 9 1.51† 1.56†
Ubiquinol-cytochrome c reductase core protein 1 1.31† 1.10
Cytochrome c oxidase subunit IV isoform 1 1.30 1.32†
ATP synthase coupling factor 6 (ATPase subunit F6) 1.29 1.25
FAO
Acyl-coenzyme A dehydrogenase, medium chain 1.52† 0.96
Acyl-coenzyme A dehydrogenase, long chain 1.48† 0.89
Acyl-coenzyme A acyltransferase 2 1.32† 0.75*
Brain
Oxidative phosphorylation
NADH dehydrogenase (ubiquinone) flavoprotein 1 1.07 0.99
NADH dehydrogenase (ubiquinone) 1  subcomplex, 9 0.83 0.90
Ubiquinol-cytochrome c reductase core protein 1 0.94 0.99
Cytochrome c oxidase subunit IV isoform 1 0.95 1.01
ATP synthase coupling factor 6 (ATPase subunit F6) 0.93 1.16
FAO
Acyl-coenzyme A dehydrogenase, medium chain 1.30† 1.12
Acyl-coenzyme A dehydrogenase, long chain 1.15† 1.25†
Acyl-coenzyme A acyltransferase 2 1.03 1.27†
Heart
Oxidative phosphorylation
NADH dehydrogenase (ubiquinone) flavoprotein 1 0.79* 0.87
NADH dehydrogenase (ubiquinone) 1  subcomplex, 9 0.76* 0.93
Ubiquinol-cytochrome c reductase core protein 1 0.84* 0.88
Cytochrome c oxidase subunit IV isoform 1 0.88 1.11
ATP synthase coupling factor 6 (ATPase subunit F6) 0.52* 1.04
FAO
Acyl-coenzyme A dehydrogenase, medium chain 0.71* 1.03
Acyl-coenzyme A dehydrogenase, long chain 0.90 1.14†
Acyl-coenzyme A acyltransferase 2 1.17 1.41†
Kidney
Oxidative phosphorylation
NADH dehydrogenase (ubiquinone) flavoprotein 1 1.04 1.09
NADH dehydrogenase (ubiquinone) 1  subcomplex, 9 1.04 1.01
Ubiquinol-cytochrome c reductase core protein 1 0.93 1.05
Cytochrome c oxidase subunit IV isoform 1 0.99 1.09
ATP synthase coupling factor 6 (ATPase subunit F6) 1.15 1.03
FAO
Acyl-coenzyme A dehydrogenase, medium chain 0.96 0.94
Acyl-coenzyme A dehydrogenase, long chain 0.96 1.18†
Acyl-coenzyme A acyltransferase 2 1.26 1.69†
*Significantly downregulated gene/protein. †Significantly upregulated gene/protein. Symbols indicate a significant difference (P  0.05)
compared with wild type.
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type. In contrast, two of seven FAO proteins were signifi-
cantly induced in brain mitochondria and the remaining
proteins were uniformly greater than wild type. In cardiac
mitochondria, three of seven FAO proteins were significantly
induced, and with one exception the remaining proteins were
greater than wild type. In kidney mitochondria of Akita, four
of eight FAO proteins were significantly induced, while only
one protein was significantly repressed.
Proteins of the tricarboxylic acid cycle. Tricarboxylic
acid (TCA) cycle proteins were coordinately induced in
kidney mitochondria of Akita (6 of 10 proteins) (Table 1). In
contrast, 3 of 10 TCA cycle proteins (citrate synthase, isocit-
rate dehydrogenase 3 [NAD] , and malate dehydrogenase
2) were significantly repressed in cardiac mitochondria, and
of the remaining proteins only one was greater than wild-type
levels. In liver and brain mitochondria, TCA cycle proteins
were unaffected by diabetes, with no significantly regulated
proteins in liver mitochondria. Only one TCA protein, isocit-
rate dehydrogenase 3 (NAD) , was significantly repressed
in brain mitochondria of Akita mice.
Proteins of oxidative phosphorylation. Protein levels
of OXPHOS subunits were coordinately induced in liver
mitochondria of Akita mice (14 of 26 proteins), including
subunits of complexes I, II, III, and IV (Table 1). In
contrast, three OXPHOS subunits were significantly re-
pressed in cardiac mitochondria, and of the remaining 24
proteins, 67% were lower than wild-type levels. In brain
and kidney mitochondria, OXPHOS subunits were gener-
ally not regulated. Only 2 of 29 OXPHOS subunits were
significantly increased in brain mitochondria, and only 1 of
28 OXPHOS subunits was significantly increased in kidney
mitochondria of Akita.
Expression of nuclear-encoded mitochondrial genes.
We determined if diabetes-induced transcriptional changes
of energy metabolism enzymes predicted mitochondrial
protein composition in each tissue. In liver, expression of
FAO and OXPHOS genes increased, but their transcrip-
tional regulators did not (Fig. 2A). Thus, OXPHOS gene
expression mirrored proteomic changes in liver mitochon-
dria, but the direction of change in FAO gene expression
was discordant with protein changes. This observation is
illustrated in Table 2, which compares the expression
levels of investigated FAO and OXPHOS genes with their
respective mitochondrial protein levels. In contrast, gene
expression was generally reduced in cardiac tissue (Fig.
2B). Expression of OXPHOS subunit genes and the FAO
protein medium-chain acyl CoA dehydrogenase was signif-
icantly reduced. These transcriptional changes were ac-
companied by reduced expression of PGC-1, PGC-1
,
estrogen-related receptor , mitochondrial transcription
factor-A, and PPAR. Thus, OXPHOS gene expression
mirrored proteomic changes in heart mitochondria, but
the direction of change in FAO gene expression was
discordant with the change in mitochondrial FAO proteins
(Table 2). In the brain, expression of PGC-1, PGC-1
,
and nuclear respiratory factor-1 was increased; however,
none of the OXPHOS genes were induced (Fig. 2C). With
respect to FAO, PPAR expression was unchanged, but
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expression of two FAO genes increased. Thus, the brain
was the only tissue in which changes in FAO gene expres-
sion tended to mirror changes in the mitochondrial pro-
teome (Table 2). Despite the large number of regulated
proteins in kidney mitochondria, expression levels of the
genes investigated were not significantly different between
wild-type and Akita kidneys (Fig. 2D). In summary, with
the exception of the brain, gene expression changes did
not predict changes in FAO proteins, whereas trends
in OXPHOS gene expression paralleled mitochondrial
OXPHOS subunit protein content in all tissues.
Mitochondrial function. The TCA cycle and the respira-
tory chain are important determinants of mitochondrial
respiratory function, and proteins of these energy meta-
bolic pathways were significantly regulated in Akita liver,
heart, and kidney mitochondria. We therefore measured
mitochondrial respiration rates and ATP synthesis in iso-
lated mitochondria. Despite a coordinate induction of
OXPHOS subunits in liver mitochondria and a coordinate
induction of TCA cycle proteins in kidney mitochondria of
Akita, both state 3 respiration and ATP synthesis were
unchanged in both tissues, using succinate or glutamate as
the substrate (Fig. 3A, C, D, and F and Fig. 4A, C, D, and F).
These findings were confirmed in respiration measure-
ments in which oxygen consumption was stimulated with
the uncoupling agent FCCP, both using succinate or
glutamate as substrates (Fig. 3B and E and Fig. 4B and E).
Mitochondrial function was also not enhanced in these
tissues using palmitoyl-carnitine as a substrate, except for
a significant increase in state 3 respiration in kidney
mitochondria of Akita mice (Fig. 3G and H and Fig. 4G and
H). In contrast, state 3 respiration, FCCP-stimulated res-
piration, and ATP synthesis were reduced in cardiac
mitochondria of Akita mice, both with glutamate and
succinate as a substrate (Fig. 5A–F). ATP-to-O ratios were
not different in liver, kidney, or heart mitochondria with
any substrate (Fig. 3I and Fig. 4I and Fig. 5G).
Because we observed decreased mitochondrial H2O2 pro-
duction in Akita hearts in our previous study (3), we also
measured H2O2 generation in mitochondria obtained from
liver and kidney tissues of wild-type and Akita mice. In liver
mitochondria, succinate-driven H2O2 production was mark-
edly decreased in Akita mice (supplementary Fig. S16A). In
kidney mitochondria, H2O2 production was not different
between the groups (supplementary Fig. S16B). In mitochon-
dria of wild-type and Akita mice, hepatic and renal H2O2
generation were markedly decreased following addition of
the complex I inhibitor rotenone.
Tissue ultrastructure. We recently reported altered mito-
chondrial morphology in hearts of 24-week-old Akita mice,
characterized by markedly reduced cristae density and in-
creased mitochondrial volume density (3). Therefore, we
also evaluated mitochondrial morphology in liver, brain,
heart, and kidney tissues of 12-week-old Akita mice in this
study. Mitochondrial morphology was not different between
wild-type and Akita mice in liver, brain, and kidney tissue
(Fig. 6A–C). However, mitochondrial cristae density was
clearly reduced in cardiac tissue of Akita mice (Fig. 6D).
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Mitochondrial volume density and mitochondrial number in
kidney and liver tissue, quantified by stereology, were not
different between wild-type and Akita mice (Fig. 6E and F).
In contrast, both mitochondrial volume density and number
were increased in Akita hearts (Fig. 6E and F).
DISCUSSION
In the present study, we show that type 1 diabetes causes
tissue-specific remodeling of the proteome involved in
mitochondrial energy metabolism. The hepatic mitochon-
drial proteome was regulated to the greatest extent (41%
of all identified proteins), and the cerebral mitochondrial
proteome was regulated the least (13%). The tissue-spe-
cific remodeling is not surprising, considering that the
mitochondrial proteome composition is quite different
among tissues, even in normal animals (24,25). The fact
that proteins of substrate metabolism were regulated to
the greatest extent in liver mitochondria of Akita appears
plausible, since the liver plays a central role in the
regulation of systemic glucose metabolism, such as main-
tenance of glucose concentrations by modulating glucone-
ogenesis under fed and fasted conditions (26). Thus,
hepatic energy metabolism may be particularly sensitive to
diabetes-associated changes in systemic concentrations of
glucose and insulin.
With the exception of the brain, mitochondrial FAO
protein levels did not parallel FAO gene expression in
Akita mice. In the liver, FAO gene expression was in-
creased, whereas mitochondrial FAO protein content was
reduced. Similarly, FAO gene expression was reduced but
FAO protein levels were increased in cardiac tissue, and
FAO protein content was increased but FAO gene expres-
sion was unchanged in kidney tissue, suggesting that
mRNA levels do not predict FAO capacity in liver, heart,
and kidney tissue of Akita. Alternative mechanisms that
regulate mitochondrial FAO protein content could include
1) increased mRNA translation, 2) decreased protein
turnover, or 3) increased import of proteins into the
mitochondrion. Modulation of protein translation has been
suggested in studies showing that hyperglycemia and
hyperinsulinemia increase mRNA elongation and transla-
tion via dephosphorylation of eukaryotic elongation factor
2 in proximal tubular epithelial cells and that eukaryotic
elongation factor 2 phosphorylation is reduced in renal
cortex of type 2 diabetic db/db mice (27). Support also
exists for the hypothesis that diabetes may regulate mito-
chondrial protein import in Akita. The translocase of the
inner mitochondrial membrane 44 is induced in kidneys of
streptozotocin-induced diabetic mice, and gene delivery of
translocase of the inner mitochondrial membrane 44 in-
creases mitochondrial import of manganese superoxide
dismutase and glutathione reductase (28,29). Thus, future
studies will be conducted to determine whether changes in
the regulation of mRNA translation or mitochondrial im-
port might regulate protein levels of FAO enzymes inde-
pendently of changes in gene expression.
The TCA cycle and electron transport chain are impor-
tant determinants of mitochondrial function. Since the
proteome of these pathways was significantly remodeled
in hepatic, cardiac, and renal mitochondria of Akita, we
measured mitochondrial respiration and ATP synthesis
rates. Despite the coordinate induction of OXPHOS sub-
units in liver mitochondria and the coordinate induction of
TCA cycle enzymes in kidney mitochondria, state 3 respi-
ration, FCCP-stimulated respiration, and ATP synthesis
did not increase. The absence of differences in liver, brain
or kidney mitochondrial function between Akita and non-
diabetic controls could indicate a true absence of mito-
chondrial dysfunction in these tissues. It has to be
acknowledged, though, that we investigated at a relatively
early stage. Six weeks of diabetes might not have been
sufficient to cause mitochondrial damage in liver, brain,
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and kidney tissue, and whether a longer duration of
diabetes could impair mitochondrial function in these
tissues cannot be ruled out. Since insulin signaling may
regulate mitochondrial function (30), low but measurable
levels of insulin in the Akita mouse may partially offset the
detrimental effect of diabetes and/or insulin deficiency on
mitochondrial function in this model. Alternatively, the
increase in protein content in certain mitochondrial path-
ways may reflect compensatory changes that offset im-
paired function elsewhere. Thus, the fact that proteomic
changes do not reflect or predict actual metabolic flux
rates in these tissues emphasizes the importance of using
a systems biology approach including metabolite measure-
ments (metabolomics) in combination with comparative
proteomics to better inform the complex interaction of
transcriptional and protein changes in the adaptation of
mitochondria to diabetes. Our findings contrast with other
studies that have reported impaired mitochondrial func-
tion in livers and kidneys of streptozotocin-induced dia-
betic models (5,8–10). Moreover, no impairment in
mitochondrial morphology was observed in these tissues.
Thus, the Akita model appears to be a unique model of
type 1 diabetes that is relatively resistant to diabetes-
induced mitochondrial damage in liver and kidney and
may reflect the fact that these mice produce measurable
amounts of insulin despite severe hyperglycemia (18).
In contrast to liver and kidney, mitochondrial function
was impaired in Akita hearts using glutamate and succi-
nate as substrates. Functional impairment was associated
with reduced protein content of TCA cycle enzymes and
OXPHOS subunits in Akita. At the gene level, mRNA
content of four of five OXPHOS genes examined was
reduced in Akita hearts, and there was a coordinate
repression of the transcriptional regulators of mitochon-
drial mass and function (i.e., PGC-1, PGC-1
, TFAm, and
ERR). Thus, these results suggest that reduced signaling
via the PGC-1 transcriptional regulatory cascade may
contribute to reduced TCA cycle and OXPHOS subunit
content, leading to compromised mitochondrial function
in Akita diabetic hearts. Oxidative damage unlikely con-
tributes to reduced respiration rates since mitochondrial
reactive oxygen species production and oxidative damage
are not increased in hearts of the Akita mouse model (3).
We cannot rule out that other mechanisms such as altered
mitochondrial membrane lipid content or changes in gly-
cosylation of mitochondrial proteins, which are proposed
mechanisms for mitochondrial dysfunction in diabetes
(31,32), may contribute to impaired cardiac mitochondrial
function in Akita hearts. Based on the impairment in
mitochondrial function and morphology, cardiac mito-
chondria appear to be affected to the greatest extent in
12-week-old type 1 diabetic Akita mice, relative to other
tissues, underscoring an important role for mitochondrial
dysfunction in cardiac complications of type 1 diabetes.
Analysis of the cardiac mitochondrial proteome re-
vealed increased abundance of three FAO enzymes:
long-chain acetyl-CoA dehydrogenase, acetyl-CoA acyl-
transferase 2, and hydroxyacyl-CoA dehydrogenase, all
of which are essential components of the 
-oxidation
spiral. This induction is consistent with increased car-
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diac FAO rates in the Akita mouse and other type 1
diabetic models (3,33). It is widely accepted that in-
creased PPAR activity increases fatty acid oxidative
capacity in diabetic hearts. Indeed, gene expression of
PPAR and its target genes increases in streptozotocin-
induced diabetic mice, and transgenic overexpression of
PPAR in cardiomyocytes results in a metabolic pheno-
type similar to the diabetic heart (34). However, despite
increased serum free fatty acid and triglyceride levels in
the Akita mouse, expression of PPAR and its target
gene medium-chain acyl CoA dehydrogenase was re-
duced in Akita hearts (3), suggesting either that in-
creased FAO protein content may not be regulated by
PPAR in Akita hearts or the existence of additional
regulatory mechanisms that determine fatty acid oxida-
tive capacity in Akita hearts, as discussed above.
In conclusion, tissue-specific remodeling of the pro-
teome of mitochondrial energy metabolism in type 1
diabetic Akita mice was demonstrated. This remodeling
was only partially mediated by transcriptional mecha-
nisms. Despite remodeling of the mitochondrial proteome
in all tissues investigated, impaired mitochondrial function
was only observed in cardiac mitochondria, which we
believe reflects greater repression of PGC-1 signaling in
the heart relative to other tissues. These results confirm an
important role of mitochondrial dysfunction in the patho-
genesis of cardiac complications in type 1 diabetes.
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